CARSGEN Revenue and Competitors

Shanghai,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CARSGEN's estimated annual revenue is currently $27M per year.(i)
  • CARSGEN's estimated revenue per employee is $155,000

Employee Data

  • CARSGEN has 174 Employees.(i)
  • CARSGEN grew their employee count by -2% last year.

CARSGEN's People

NameTitleEmail/Phone
1
Co-founder, Chairman the Board, CEO, CSOReveal Email/Phone
2
Co-founder and COOReveal Email/Phone
3
SVP - Global Regulatory AffairsReveal Email/Phone
4
Director Clinical Operations and Data SciencesReveal Email/Phone
5
Clinical ScientistReveal Email/Phone
6
Administrative SupervisorReveal Email/Phone
7
Supply Chain ManagementReveal Email/Phone
8
QC Microbiology Analyst 1Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is CARSGEN?

CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T and antibody therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the United States. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-Claudin18.2-T for gastric and pancreatic cancer, CAR-GPC3-T for hepatocellular carcinoma (HCC) and squamous lung cancer and CAR-EGFR/EGFRvIII-T for glioblastoma. CARsgen also has ongoing clinical programs with a fully human CAR-BCMA-T for multiple myeloma and a humanized CAR-CD19-T for leukemia. CARsgen's proprietary antibody platform enables the development of therapeutic antibodies. Its leading humanized monoclonal antibody targeting Claudin18.2 has obtained IND approval from the NMPA.

keywords:N/A

N/A

Total Funding

174

Number of Employees

$27M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CARSGEN News

2022-04-17 - CAR T-Cell Therapy Market Size And Forecast | CARsgen ...

CARsgen Therapeutics, Novartis International AG, Pfizer Kite Pharma Legend Biotech, Juno Therapeutics, Aurora Biopharma Inc., Bluebird Bio...

2022-04-06 - CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment...

2022-04-06 - Project Profile: CARsgen Therapeutics GMP Manufacturing ...

A: CARsgen plans to manufacture innovative CAR T cell therapy products in the RTP Manufacturing Facility to support its clinical studies and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.2M177-3%N/A
#2
$39.6M17833%N/A
#3
$52.3M1948%N/A
#4
$30.4M1961%N/A
#5
$46.5M206-1%N/A